Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

5-HT induces PPAR γ reduction and proliferation of pulmonary artery smooth muscle cells via modulating GSK-3β/β-catenin pathway.

Ke R, Xie X, Li S, Pan Y, Wang J, Yan X, Zang W, Gao L, Li M.

Oncotarget. 2017 Aug 24;8(42):72910-72920. doi: 10.18632/oncotarget.20582. eCollection 2017 Sep 22.

2.

Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway.

Zhang Z, Zhang L, Sun C, Kong F, Wang J, Xin Q, Jiang W, Li K, Chen O, Luan Y.

Oncotarget. 2017 Jun 28;8(38):63430-63441. doi: 10.18632/oncotarget.18825. eCollection 2017 Sep 8.

3.

Prostaglandin E1 Attenuates Pulmonary Artery Remodeling by Activating Phosphorylation of CREB and the PTEN Signaling Pathway.

Lai YJ, Hsu HH, Chang GJ, Lin SH, Chen WJ, Huang CC, Pang JS.

Sci Rep. 2017 Aug 30;7(1):9974. doi: 10.1038/s41598-017-09707-y.

4.

PPARγ attenuates hypoxia-induced hypertrophic transcriptional pathways in the heart.

Chaudhry A, Carthan KA, Kang BY, Calvert J, Sutliff RL, Michael Hart C.

Pulm Circ. 2017 Mar 13;7(1):98-107. doi: 10.1086/689749. eCollection 2017 Mar.

5.

Altered expression of PPAR‑γ and TRPC in neonatal rats with persistent pulmonary hypertension.

Du Y, Fu J, Yao L, Qiao L, Liu N, Xing Y, Xue X.

Mol Med Rep. 2017 Aug;16(2):1117-1124. doi: 10.3892/mmr.2017.6744. Epub 2017 Jun 9.

6.

Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study.

Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, Gibbs JSR, Condliffe R, Elliot CA, Kiely DG, Simonneau G, Montani D, Sitbon O, Gall H, Schermuly RT, Ghofrani HA, Lawrie A, Humbert M, Wilkins MR.

Lancet Respir Med. 2017 Sep;5(9):717-726. doi: 10.1016/S2213-2600(17)30161-3. Epub 2017 Jun 15.

7.

BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.

Orriols M, Gomez-Puerto MC, Ten Dijke P.

Cell Mol Life Sci. 2017 Aug;74(16):2979-2995. doi: 10.1007/s00018-017-2510-4. Epub 2017 Apr 26. Review. Erratum in: Cell Mol Life Sci. 2017 May 23;:.

8.

Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.

Harvey LD, Chan SY.

J Clin Med. 2017 Apr 4;6(4). pii: E43. doi: 10.3390/jcm6040043. Review.

9.

Severe pulmonary hypertension in aging female apolipoprotein E-deficient mice is rescued by estrogen replacement therapy.

Umar S, Partow-Navid R, Ruffenach G, Iorga A, Moazeni S, Eghbali M.

Biol Sex Differ. 2017 Mar 20;8:9. doi: 10.1186/s13293-017-0129-7. eCollection 2017.

11.

Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).

Barnes JW, Tonelli AR, Heresi GA, Newman JE, Mellor NE, Grove DE, Dweik RA.

Pulm Circ. 2016 Dec;6(4):439-447. doi: 10.1086/688847. Review.

12.

Multi-omics analysis reveals regulators of the response to PDGF-BB treatment in pulmonary artery smooth muscle cells.

Chen J, Cui X, Qian Z, Li Y, Kang K, Qu J, Li L, Gou D.

BMC Genomics. 2016 Oct 6;17(1):781.

13.

Role of oxidized lipids in pulmonary arterial hypertension.

Sharma S, Ruffenach G, Umar S, Motayagheni N, Reddy ST, Eghbali M.

Pulm Circ. 2016 Sep;6(3):261-73. doi: 10.1086/687293. Review.

14.

Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):583-595. doi: 10.1164/rccm.201607-1515PP. Review. No abstract available.

PMID:
27649290
15.

Loss of prolyl hydroxylase domain protein 2 in vascular endothelium increases pericyte coverage and promotes pulmonary arterial remodeling.

Wang S, Zeng H, Xie XJ, Tao YK, He X, Roman RJ, Aschner JL, Chen JX.

Oncotarget. 2016 Sep 13;7(37):58848-58861. doi: 10.18632/oncotarget.11585.

16.

Peroxisome Proliferator-Activated Receptor γ Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung.

Kang BY, Park K, Kleinhenz JM, Murphy TC, Sutliff RL, Archer D, Hart CM.

Am J Respir Cell Mol Biol. 2017 Jan;56(1):131-144. doi: 10.1165/rcmb.2016-0166OC.

17.

Update on novel targets and potential treatment avenues in pulmonary hypertension.

Huetsch JC, Suresh K, Bernier M, Shimoda LA.

Am J Physiol Lung Cell Mol Physiol. 2016 Nov 1;311(5):L811-L831. doi: 10.1152/ajplung.00302.2016. Epub 2016 Sep 2.

18.

Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension.

Yuan K, Shao NY, Hennigs JK, Discipulo M, Orcholski ME, Shamskhou E, Richter A, Hu X, Wu JC, de Jesus Perez VA.

Am J Pathol. 2016 Sep;186(9):2500-14. doi: 10.1016/j.ajpath.2016.05.016. Epub 2016 Jul 25.

19.

Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells.

Blum JI, Bijli KM, Murphy TC, Kleinhenz JM, Hart CM.

Am J Med Sci. 2016 Jul;352(1):71-9. doi: 10.1016/j.amjms.2016.03.019. Epub 2016 Apr 4.

20.

Update in Pulmonary Vascular Disease 2015.

Maron BA, Gladwin MT, Simon MA.

Am J Respir Crit Care Med. 2016 Jun 15;193(12):1337-44. doi: 10.1164/rccm.201601-0143UP. Review. No abstract available.

Supplemental Content

Support Center